Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27155740

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Jun
First author
Duchesne GM

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jun;17(6):683-684. doi: 10.1016/S1470-2045(16)00149-2.
    note
    Source null
    related pmid
    27155739
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Jun;17(6):e223. doi: 10.1016/S1470-2045(16)30169-3.
    note
    Source null
    related pmid
    27299275
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2016 Aug;17(8):e313-e314. doi: 10.1016/S1470-2045(16)30282-0.
    note
    Source null
    related pmid
    27511148
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2016 Aug;17(8):e313. doi: 10.1016/S1470-2045(16)30309-6.
    note
    Source null
    related pmid
    27511149
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2017 Sep;18(9):e510. doi: 10.1016/S1470-2045(17)30575-2.
    note
    Source null
    related pmid
    28760401
    relationship
    Erratum in

Authors and identifiers

  1. name
    Duchesne GM
    type
    Author
  2. name
    Woo HH
    type
    Author
  3. name
    Bassett JK
    type
    Author
  4. name
    Bowe SJ
    type
    Author
  5. name
    D'Este C
    type
    Author
  6. name
    Frydenberg M
    type
    Author
  7. name
    King M
    type
    Author
  8. name
    Ledwich L
    type
    Author
  9. name
    Loblaw A
    type
    Author
  10. name
    Malone S
    type
    Author
  11. name
    Millar J
    type
    Author
  12. name
    Milne R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Duchesne GM
    type
    Author
  2. name
    Woo HH
    type
    Author
  3. name
    Bassett JK
    type
    Author
  4. name
    Bowe SJ
    type
    Author
  5. name
    D'Este C
    type
    Author
  6. name
    Frydenberg M
    type
    Author
  7. name
    King M
    type
    Author
  8. name
    Ledwich L
    type
    Author
  9. name
    Loblaw A
    type
    Author
  10. name
    Malone S
    type
    Author
  11. name
    Millar J
    type
    Author
  12. name
    Milne R
    type
    Author
bibliography ids
  1. nci-bib-3fcfcd0be0856b686fbc809f
book metadata
content sha256
efa9addea3fac080b103cb74e3b14bc01d3468211c84896655cea15ab7ea7c49
document type
citation
dois
  1. 10.1016/S1470-2045(16)00107-8
electronic publication date
display
2016 May 4
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27155740
immutable id
pubmed:27155740@efa9addea3fac080b103cb74e3b14bc01d3468211c84896655cea15ab7ea7c49
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
727-737
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jun;17(6):683-684. doi: 10.1016/S1470-2045(16)00149-2.
    note
    Source null
    related pmid
    27155739
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Jun;17(6):e223. doi: 10.1016/S1470-2045(16)30169-3.
    note
    Source null
    related pmid
    27299275
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2016 Aug;17(8):e313-e314. doi: 10.1016/S1470-2045(16)30282-0.
    note
    Source null
    related pmid
    27511148
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2016 Aug;17(8):e313. doi: 10.1016/S1470-2045(16)30309-6.
    note
    Source null
    related pmid
    27511149
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2017 Sep;18(9):e510. doi: 10.1016/S1470-2045(17)30575-2.
    note
    Source null
    related pmid
    28760401
    relationship
    Erratum in
outcomes validated
false
pmid
27155740
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
a47a31fc7b880e201a6bad5ed1919c877546d40a0260ef2ae0b78c2c5b3d1fe0
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Jun
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27155740/
title
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Preserved source evidence · Not medical advice